KR20180095738A - 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 - Google Patents

안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 Download PDF

Info

Publication number
KR20180095738A
KR20180095738A KR1020187023806A KR20187023806A KR20180095738A KR 20180095738 A KR20180095738 A KR 20180095738A KR 1020187023806 A KR1020187023806 A KR 1020187023806A KR 20187023806 A KR20187023806 A KR 20187023806A KR 20180095738 A KR20180095738 A KR 20180095738A
Authority
KR
South Korea
Prior art keywords
adamts13
formulation
preferred
stabilized
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187023806A
Other languages
English (en)
Korean (ko)
Inventor
하 페터 마티센
페터 엘 투레섹
한스-페터 슈바르츠
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20180095738A publication Critical patent/KR20180095738A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187023806A 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제 Ceased KR20180095738A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
US61/244,353 2009-09-21
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127009803A Division KR101891646B1 (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035791A Division KR20190137954A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Publications (1)

Publication Number Publication Date
KR20180095738A true KR20180095738A (ko) 2018-08-27

Family

ID=43598388

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020187023806A Ceased KR20180095738A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020197035791A Ceased KR20190137954A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020247043292A Pending KR20250008986A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020227034508A Ceased KR20220139456A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020217013486A Ceased KR20210054598A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020127009803A Active KR101891646B1 (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020197035791A Ceased KR20190137954A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020247043292A Pending KR20250008986A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020227034508A Ceased KR20220139456A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020217013486A Ceased KR20210054598A (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
KR1020127009803A Active KR101891646B1 (ko) 2009-09-21 2010-09-21 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제

Country Status (21)

Country Link
US (9) US8623352B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP4467160A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5819303B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (6) KR20180095738A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN104224705B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010295299B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012006283B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2774556A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (4) DK3834841T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA024267B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (4) ES2865250T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI3834841T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR24C1049I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20160295T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE028688T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN02645A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (3) MX362382B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ598839A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (4) PL3834841T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT4218797T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011035335A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065742A1 (en) 2008-12-05 2010-06-10 Baxter International Inc. Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
CA2774556A1 (en) 2009-09-21 2011-03-24 Baxter Healthcare S.A. Stabilized liquid and lyophilized adamts13 formulations
DK2814514T3 (en) * 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
US10441531B2 (en) * 2012-11-09 2019-10-15 Bloodworks Protein stabilizing factors
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
CA2952609A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
EP3401685B1 (en) 2016-01-08 2021-12-01 Kyoto University Diagnostic method and medicine comprising adamts13 as main ingredient
EA201990373A1 (ru) * 2016-08-04 2019-07-31 Баксалта Инкорпорэйтед Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме
ES2981519T3 (es) 2016-11-04 2024-10-09 Takeda Pharmaceuticals Co Formulaciones de virus adeno-asociados
DK3612215T3 (da) 2017-04-20 2024-10-28 Atyr Pharma Inc Sammensætninger til behandling af lungeinflammation
KR102720834B1 (ko) * 2017-07-25 2024-10-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Il-15 단백질 복합체 약학 조성물 및 이의 용도
CA3104196A1 (en) * 2018-07-11 2020-01-16 Baxalta Incorporated Aav compositions
EP4037704A4 (en) 2019-10-04 2023-04-26 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
AU2021248679A1 (en) 2020-04-02 2022-10-27 Takeda Pharmaceutical Company Limited ADAMTS13 variant, compositions, and uses thereof
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
IL300596A (en) * 2020-08-13 2023-04-01 Hadasit Medical Res Services & Development Limited Mutants of disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (adamts-13), preparations and their uses in therapeutic methods
EP4490042A1 (en) 2022-03-08 2025-01-15 Equashield Medical Ltd. Fluid transfer station in a robotic pharmaceutical preparation system
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2541470T3 (es) 1999-02-22 2015-07-20 University Of Connecticut Formulaciones de factor VIII libres de albúmina
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
EP1642128B1 (en) * 2003-07-07 2016-11-16 University Of North Carolina At Chapel Hill Method and system for detection of von willebrand factor (vwf) multimers
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL1902141T3 (pl) * 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
EP2522717B1 (en) 2006-01-04 2014-04-02 Baxter International Inc Oligopeptide-free cell culture media
CA2774556A1 (en) * 2009-09-21 2011-03-24 Baxter Healthcare S.A. Stabilized liquid and lyophilized adamts13 formulations
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
US12178861B2 (en) 2024-12-31
US20180207245A1 (en) 2018-07-26
ES2948612T3 (es) 2023-09-14
US10758599B2 (en) 2020-09-01
NZ598839A (en) 2014-03-28
US9937244B2 (en) 2018-04-10
EP4218797B9 (en) 2025-04-30
CN102573792A (zh) 2012-07-11
US8623352B2 (en) 2014-01-07
US20190247475A1 (en) 2019-08-15
ES2579906T3 (es) 2016-08-17
DK4218797T5 (da) 2025-07-21
AU2010295299A1 (en) 2012-04-12
ES2865250T3 (es) 2021-10-15
HK1173968A1 (zh) 2013-05-31
US20250099559A1 (en) 2025-03-27
EP4218797A1 (en) 2023-08-02
DK3834841T3 (da) 2023-06-06
BR112012006283A2 (pt) 2016-05-31
FI3834841T3 (fi) 2023-06-05
WO2011035335A2 (en) 2011-03-24
EP3167897A1 (en) 2017-05-17
US11564979B2 (en) 2023-01-31
KR101891646B1 (ko) 2018-08-27
PL3834841T3 (pl) 2023-07-24
DK4218797T3 (da) 2024-12-09
PL3167897T3 (pl) 2021-09-27
US20200376098A1 (en) 2020-12-03
US20110229455A1 (en) 2011-09-22
KR20220139456A (ko) 2022-10-14
CN104224705A (zh) 2014-12-24
EP3167897B1 (en) 2021-01-27
CA2774556A1 (en) 2011-03-24
AU2010295299B2 (en) 2015-12-24
JP2013505270A (ja) 2013-02-14
KR20120099646A (ko) 2012-09-11
KR20250008986A (ko) 2025-01-16
EP3834841A1 (en) 2021-06-16
KR20190137954A (ko) 2019-12-11
MX2012003414A (es) 2012-06-19
US20230130866A1 (en) 2023-04-27
EP2480198B1 (en) 2016-03-09
IN2012DN02645A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-11
EA024267B1 (ru) 2016-09-30
EP4467160A2 (en) 2024-11-27
EP2480198B9 (en) 2016-11-23
US9572778B2 (en) 2017-02-21
JP2015063556A (ja) 2015-04-09
CN102573792B (zh) 2014-10-15
HRP20160295T1 (hr) 2016-05-20
MX362382B (es) 2019-01-14
MX2019000547A (es) 2020-11-12
PT4218797T (pt) 2024-12-09
MX339205B (es) 2016-05-16
US9351935B2 (en) 2016-05-31
HUE028688T2 (en) 2017-01-30
WO2011035335A3 (en) 2011-12-01
CN104224705B (zh) 2018-02-02
EA201200519A1 (ru) 2012-09-28
EP3834841B1 (en) 2023-05-17
PL2480198T3 (pl) 2016-09-30
EP2480198A2 (en) 2012-08-01
EP4467160A3 (en) 2025-01-15
EP4218797B1 (en) 2024-09-11
DK2480198T3 (en) 2016-03-29
PT3834841T (pt) 2023-06-19
US10238720B2 (en) 2019-03-26
BR112012006283B1 (pt) 2022-03-15
PL4218797T3 (pl) 2025-02-10
DK3167897T3 (da) 2021-04-19
FI4218797T3 (fi) 2024-12-07
ES3001509T3 (en) 2025-03-05
US20160375111A1 (en) 2016-12-29
US20140178357A1 (en) 2014-06-26
JP5819303B2 (ja) 2015-11-24
KR20210054598A (ko) 2021-05-13
US20170112906A1 (en) 2017-04-27
FR24C1049I1 (fr) 2025-01-17

Similar Documents

Publication Publication Date Title
US12178861B2 (en) Stabilized liquid and lyophilized ADAMTS13 formulations
HK40097428B (en) Stabilized liquid and lyophilized adamts13 formulations
HK40097428A (en) Stabilized liquid and lyophilized adamts13 formulations
HK40051221A (en) Stabilized liquid and lyophilized adamts13 formulations
HK40051221B (en) Stabilized liquid and lyophilized adamts13 formulations
HK1237675A1 (en) Stabilized liquid and lyophilized adamts13 formulations
HK1237675B (en) Stabilized liquid and lyophilized adamts13 formulations
HK1173968B (en) Stabilized liquid and lyophilized adamts13 formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180817

Application number text: 1020127009803

Filing date: 20120417

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180917

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181101

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190513

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181101

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190513

Comment text: Decision to Refuse Application

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190903

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190812

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190513

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181101

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191203

Application number text: 1020127009803

Filing date: 20120417